Adamax

Semax's cognitive enhancement effects are the most consistently documented in its research base: improved performance in conditioned avoidance tests, memory consolidation tasks, and learning paradigms in animal models; human open-label data from Russian clinical programs for vascular dementia, cognitive impairment, and neurological rehabilitation. The mechanisms (BDNF upregulation, TrkB sensitization, MC4R-mediated catecholamine modulation) provide a coherent biological basis. Community users describe Adamax as producing sharper focus, faster mental processing, and improved working memory — qualitatively consistent with Semax but subjectively described as 'stronger' and 'more sustained.' Whether this subjective description reflects genuine pharmacological superiority of Adamax over N-Acetyl-Semax, or reflects expectation effects in users who have sought out Adamax specifically for its marketed potency claims, cannot be determined without controlled comparison data. Grade B for Semax cognitive effects. Grade X for Adamax-specific cognitive enhancement.

Semax's neuroprotective profile is one of its most consistently replicated findings: protection of neurons from ischemia, oxidative stress, and excitotoxicity in animal models; BDNF-mediated support of neuronal survival; improvement in post-stroke neurological outcomes in Russian clinical trials. The Stavchansky 2024 paper is the most recent independent confirmation of BDNF/TrkB transcriptional upregulation by Semax in ischemic conditions. Adamax inherits these neuroprotective claims. Whether the adamantane modification provides meaningfully better neuroprotection than standard Semax in any model — measured by infarct size, neuronal survival, or functional recovery — is not established. Grade B for Semax neuroprotection. Grade X for Adamax-specific neuroprotection.

Semax has documented anxiolytic-adjacent effects in stress models — reduced anxiety-like behavior, improved stress tolerance, and mood stabilization effects consistent with its serotonergic and cholinergic modulation. This is mechanistically distinct from Selank's more prominent anxiolytic profile (Selank works through the GABA system and enkephalin degradation inhibition). Semax's mood effects are more focused and stimulation-adjacent; Selank's are more anxiolytic-sedating. Adamax, as a Semax derivative, inherits the Semax-type profile rather than Selank's profile. Community users describe Adamax as producing 'clean cognitive stimulation' without the anxiolytic sedation of Selank analogs — consistent with the Semax mechanism. Grade B for Semax stress/mood data. Grade X for Adamax.

Some marketing materials for Adamax list 'increased endurance' as a benefit. The biological basis for this claim is thin even for Semax. BDNF has roles in skeletal muscle function and is elevated during exercise — there is basic science linking BDNF to exercise adaptation. This is a long inferential chain from 'Semax upregulates BDNF' to 'Adamax increases physical endurance.' No exercise performance study exists for Semax. No exercise performance study exists for Adamax. This claim is Grade X and should be treated as marketing language without scientific substance.

Adamax: N-Acetyl-Semax with adamantane C-terminal modification. The base Semax sequence is Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP). N-Acetylation adds an acetyl group (CH3CO-) to the N-terminal methionine. The adamantane modification at the C-terminus replaces the standard amide or carboxyl terminus with an adamantylamine group — adamantane being a cage-shaped carbon structure with four CH groups arranged in a diamond lattice, known for high lipophilicity and chemical stability. The resulting molecule: Ac-MEHFPGP-[adamantyl]. Molecular weight: approximately 1,200-1,300 Da depending on the exact connecting linker. The lipophilicity increase from the adamantane group is substantial — octanol/water partition coefficient (log P) is dramatically higher than Semax, which drives the BBB penetration claims.

TWO DIFFERENT PRODUCTS CALLED 'ADAMAX' — VERIFY BEFORE PURCHASING

Product #1 (this chapter's subject): N-Acetyl-Semax with adamantane C-terminal modification. A single structural modification of Semax incorporating both N-acetyl and adamantane groups. Typical appearance: lyophilized powder in a single vial labeled 'Adamax.' Product #2 (what some vendors sell): A physical blend of Semax and Selank in a single vial, branded 'Adamax.' Mechanistically different — two separate peptides with different mechanisms, not a structural modification of either. Same name, completely different products. Before purchasing, verify: is this a single molecular entity (N-Acetyl-Semax-Adamantane) or a Semax/Selank blend? This distinction cannot be determined from the label alone — it requires asking the vendor directly and receiving confirmation that matches a COA showing a single compound at the expected molecular weight (~1,200-1,300 Da).

Component

Origin

Evidence Grade

Contribution to Adamax

Semax base sequence (MEHFPGP)

Institute of Molecular Genetics, Russia; Russian pharma

B (Russian approval + Dolotov 2006 [1] independent)

MC4R agonism, BDNF upregulation, TrkB sensitization, neuroprotection

N-Acetyl modification

Extension of Semax chemistry; N-Acetyl-Semax is a widely available form

C-D (structural inference; N-Acetyl Semax used in some studies)

Blocks N-terminal aminopeptidase; improves BBB penetration; extends stability

Adamantane C-terminus (from P21)

P21 peptide research; adamantane drug delivery literature

C (P21 studies; general adamantane lipophilicity data)

Dramatically increases lipophilicity; blocks C-terminal carboxypeptidase; improves passive BBB diffusion

Adamax (combined molecule)

Designer peptide; community/research vendor development

X (no published study)

Combined structural stability + CNS penetration improvement — theoretical only

The adamantane modification provides exceptional stability compared to standard peptides — the cage carbon structure is chemically inert and resistant to degradation. The N-acetyl group provides additional N-terminal protection. Lyophilized Adamax: stable at -20C for 18-24 months. Reconstituted with bacteriostatic water: refrigerate at 2-8C; use within 30 days (some sources suggest longer given the exceptional stability, but 30 days is the conservative standard). Solution may appear slightly cloudy at higher concentrations due to the adamantane group's reduced water solubility — this is normal for this compound and differs from the clear solutions of standard Semax or Selank. Mass spectrometry confirming ~1,200-1,300 Da is the identity check — the molecular weight range will vary depending on the exact linker used for the adamantyl group. HPLC purity 98%+ minimum.

Key sourcing concern: the adamantane synthesis step is more complex than standard Semax synthesis. Vendors who cut corners may produce a compound where the adamantyl group is not correctly attached, producing N-Acetyl-Semax without the adamantane modification (or regular Semax without either modification). A COA showing HPLC purity 98%+ for 'Adamax' does not confirm the molecule has the adamantane group intact — only mass spectrometry at the expected molecular weight confirms the full structure is present.

Semax is an ACTH(4-7) analog that engages melanocortin receptors, particularly MC4R in the prefrontal cortex and limbic system. MC4R activation modulates dopamine and norepinephrine release in the PFC — the primary mechanism underlying Semax's cognitive and focus-enhancing effects. MC4R is also involved in appetite regulation, stress response, and mood. The MC4R activation data for Semax is well-established in Russian literature and partially replicated in Western research. Whether Adamax's adamantane modification alters its MC4R binding affinity, receptor selectivity, or agonism duration relative to Semax is not characterized in any published study. Grade B for Semax MC4R data. Grade X for Adamax-specific MC4R pharmacology.

The most widely cited mechanism for the Semax family: upregulation of brain-derived neurotrophic factor (BDNF) in hippocampus and frontal cortex. Dolotov et al. (2006, Journal of Neurochemistry) — the foundational independent paper — demonstrated a 1.4-fold increase in hippocampal BDNF protein, 1.6-fold increase in TrkB phosphorylation, and 3-fold increase in BDNF mRNA after a single Semax administration in rats (50 mcg/kg). BDNF supports neuroplasticity, long-term potentiation, neuronal survival, and synaptic consolidation — the biological basis for the 'cognitive enhancement' community narrative. Semax-induced BDNF elevation has also been confirmed in ischemic models (Stavchansky 2024 [2], PMC11498467). Adamax's BDNF claims inherit all of this. The specific question — does Adamax produce greater BDNF elevation than Semax at equivalent doses, consistent with its claimed superior potency? — has never been measured. Grade B for Semax BDNF data. Grade X for Adamax BDNF data.

TrkB is the high-affinity receptor for BDNF. When BDNF binds TrkB, it activates PI3K/Akt and MAPK/ERK pathways — the downstream signaling that drives neuroplasticity, synaptic growth, and neuroprotection. Semax appears to sensitize TrkB to BDNF — increasing the receptor's responsiveness to endogenous BDNF rather than simply increasing BDNF levels. This dual mechanism (more BDNF + more responsive TrkB) is the mechanistic foundation for the 'amplified neuroplasticity' framing. Adamax inherits this claim. Whether its structural modifications affect TrkB binding or sensitization differently from Semax is unknown. Grade B for Semax TrkB data. Grade X for Adamax.

The adamantane modification's BBB enhancement claim derives from P21 research and from the general lipophilicity argument. Adamantane has well-characterized lipophilic properties — its cage carbon structure partitions strongly into lipid membranes, improving passive diffusion across the blood-brain barrier for compounds to which it is attached. P21 (the peptide from which the adamantane group concept is borrowed) has demonstrated BBB penetration in animal models. The inference that adding the adamantane group to N-Acetyl-Semax produces proportional BBB penetration improvement is mechanistically plausible. Whether it actually does — measured by CSF concentration after intranasal or SubQ Adamax administration — has never been published. Grade C for P21 and adamantane chemistry. Grade X for Adamax-specific CNS penetration data.

The combined N-acetyl (blocks N-terminal aminopeptidase) and adamantane (blocks C-terminal carboxypeptidase) modifications should, in principle, substantially extend Adamax's resistance to the two main peptide degradation pathways relative to Semax. The theoretical result is a longer plasma half-life and a longer window of active CNS engagement. This is the primary claimed advantage over N-Acetyl-Semax alone. How much longer? Unknown. Whether the extended plasma stability translates to proportionally extended CNS activity (given that CNS penetration and receptor engagement have their own kinetics)? Unknown. Grade D: structural chemistry supports the claim; no pharmacokinetic study has measured it.

• Intranasal (preferred by community): consistent with the Russian neuropeptide tradition. The nasal route for ACTH analogs has pharmacological logic — direct nose-to-brain transport via olfactory nerves bypasses some BBB requirements, and Semax's approved Russian form is intranasal. Adamax's improved lipophilicity (adamantane group) should, in principle, enhance nasal mucosal absorption vs standard Semax. The practical reality: intranasal delivery produces highly variable bioavailability — nasal mucosal thickness, nasal congestion, spray technique, and individual anatomy all affect how much compound reaches CNS tissue. Most community users reconstitute in bacteriostatic water and use a sterile nasal spray bottle.
• SubQ injection: some community users prefer SubQ for more consistent bioavailability. The adamantane group's lipophilicity is less relevant for the SubQ route (not crossing a lipid membrane from the nasal mucosa), but the extended plasma stability benefits still apply. Standard SubQ technique.

Protocol

Route

Dose

Frequency

Cycle

Conservative / entry

Intranasal

200-300 mcg once daily (morning)

Daily

4 weeks on, 2-4 weeks off

Standard community

Intranasal

300-500 mcg once daily (morning)

Daily

4-6 weeks on, 2-4 weeks off

Higher dose

Intranasal or SubQ

500 mcg-1 mg once daily

Daily

4 weeks on, 4 weeks off

Semax reference (comparison)

Intranasal

200-900 mcg once daily

Daily

1-4 weeks on, 1-2 weeks off

Community consensus on dose reduction vs Semax: most Adamax users start at roughly 50-75% of their typical Semax dose, based on the assumption of greater potency from the structural modifications. Whether this is the right adjustment is not validated. Some users report no perceptible difference from Semax at equivalent doses; others report stronger and longer effects. Individual variation at unknown potency is a confounded experiment.

Morning dosing is the community consensus — consistent with the stimulatory/focus-enhancing profile inherited from Semax. Evening dosing risks sleep disruption. Unlike Semax (where the BDNF upregulation peak occurs within 1-3 hours and cognitive effects fade within 4-6 hours), community users report Adamax effects persisting 6-10 hours — consistent with the claimed extended half-life from the dual-modification stability improvements. Morning dosing keeps the active window within waking hours.

Adamax: lyophilized powder reconstituted with bacteriostatic water. For intranasal: reconstitute to achieve target dose per spray. A standard nasal spray pump delivers ~100 mcg per spray with proper setup. Example: 10 mg vial + 2 mL BAC water = 5,000 mcg/mL; 0.06 mL (approximately one spray in a properly calibrated pump) = 300 mcg. Test spray volume with your specific pump before calculating dose. For SubQ: standard SubQ injection technique. Solution may appear slightly opalescent at higher concentrations due to adamantane lipophilicity. Mass spectrometry confirming ~1,200-1,300 Da is the identity confirmation.

No published safety study exists for Adamax as a specific compound. The community safety signal is extrapolated from: (1) Semax's established safety profile (well-tolerated, no serious adverse events in Russian clinical use); (2) N-Acetyl-Semax's similar community experience; (3) community self-reports for Adamax specifically. The combined picture suggests a clean short-term safety profile consistent with Semax's. This does not constitute a safety study. Long-term effects of the adamantane modification, specific to this combined molecule, are completely uncharacterized.

• Mild stimulation and heightened alertness: most common community report. Expected from MC4R activation and catecholamine modulation. Dose-dependent.
• Insomnia with evening dosing: consistent with Semax's stimulatory profile. Evening dosing after 3pm is discouraged.
• Headache: occasionally reported, particularly at higher doses or first use. Usually mild and transient.
• Irritability or overstimulation: reported by some users at higher doses or in highly caffeine-sensitive individuals. Manage by reducing dose.
• Transient fatigue post-cycle: some community users report a 1-2 week 'comedown' period after ending an Adamax cycle, likely reflecting the brain's adjustment from elevated BDNF signaling returning to baseline. Not documented in any published study for Adamax; parallels what some Semax users report.
• Nasal irritation: from the intranasal route; minimized by proper spray formulation and site rotation.

Adamantane itself (the hydrocarbon compound) is used in some approved pharmaceuticals — amantadine (for influenza and Parkinson's) and memantine (for Alzheimer's dementia) are adamantane derivatives with established human safety profiles. This does not directly establish the safety of the adamantyl modification in Adamax's specific peptide-adamantane conjugate, but the general class of adamantane-modified compounds has a more established human exposure history than most novel peptide modifications. This is a meaningful nuance that distinguishes Adamax's theoretical safety profile from a purely unknown compound. That said, no study has characterized the metabolism, clearance, or tissue distribution of the Adamax-specific adamantyl conjugate in any species.

• Active psychiatric conditions (schizophrenia, bipolar disorder with psychotic features): MC4R and catecholamine modulation from Semax-class compounds is theoretically concerning in psychosis-vulnerable individuals. Avoid without psychiatric supervision.
• Pregnancy: no reproductive safety data for Adamax or Semax in humans. Avoid.
• Children: no pediatric safety data.
• Combination with MAO inhibitors or other catecholamine-affecting compounds: additive dopaminergic/noradrenergic effects possible. Discuss with physician.

Not FDA-approved. Not on the PCAC review schedule for 2026-2027 (Semax is on the July 24, 2026 PCAC agenda; Adamax is not). Research chemical only. Not a controlled substance in most jurisdictions. Not listed on the 2026 WADA Prohibited List. The regulatory trajectory of Semax through PCAC may set precedent for Adamax's eventual regulatory status, but Adamax is further behind — it lacks even Semax's Russian clinical approval that would give it an established therapeutic justification.

The community's most common combination: Semax-type compound (stimulatory, focus-enhancing, BDNF-driven) paired with Selank-type compound (anxiolytic, GABAergic, anti-stress). The Semax side addresses cognitive sharpness; the Selank side addresses the anxiety and overstimulation that Semax's catecholamine activation can produce at higher doses. Adamax in this pair brings the extended duration that Semax lacks — potentially allowing the Semax-type cognitive effects to persist throughout the day rather than fading by early afternoon. The risk: if Adamax is genuinely more potent than Semax, the standard Selank or Adalank dose that balanced Semax may be insufficient to balance Adamax. Start at lower Adamax doses when combining with Selank analogs.

Some community sources describe 'Adamax' as simply a blend of Semax and Selank — creating confusion about whether Adamax should be combined with additional Semax. For users of the structural modification compound (this chapter's subject), adding standard Semax on top of Adamax is mechanistically redundant — both activate the same MC4R pathway and BDNF cascade. Stacking Adamax with Semax adds little beyond increased risk of overstimulation without therapeutic benefit. Choose one or the other.

NAD+ is required for BDNF synthesis and for the neuronal energy production that supports the synaptic plasticity BDNF drives. The theoretical stack: Adamax (BDNF upregulation, TrkB sensitization) + NAD+ precursors (ensure adequate cofactor supply for the BDNF signaling to be translated into actual synaptic changes). Mechanistically coherent. No combination study exists.

Both Adamax and caffeine produce catecholamine-related CNS stimulation — Adamax through MC4R and dopamine/norepinephrine modulation, caffeine through adenosine receptor blockade and sympathomimetic effects. The combination is not dangerous but can produce overstimulation, jitteriness, and anxiety in sensitive individuals. If using both: reduce Adamax dose on high-caffeine days; monitor HR; avoid in afternoon. Community users with stimulant sensitivity should start with Adamax alone before adding caffeine.

All timelines below are community-derived. No published study measures Adamax's onset or duration.

Timeframe

Community-Reported (Grade E)

Minutes 30-60 (post-dose)

Onset of alertness and mental clarity reported by most community users. Consistent with Semax's known onset; slightly slower onset than some Semax users report, possibly reflecting the structural modifications' effect on absorption kinetics.

Hours 1-4

Peak cognitive effects window. Sharper focus, improved working memory, faster associative thinking. The quality of effect described as 'cleaner' than stimulant cognitive enhancement — not jittery or anxious, but alert and precise.

Hours 4-8

Where Adamax is claimed to differentiate from Semax: sustained effects through this window rather than the fade that Semax users typically report at 4-6 hours. This extended window is the primary reason users seek Adamax over its parents. Whether it is pharmacologically real or reflects expectation bias is unknown.

Hours 8-12

Effects declining. Most users report full clearance within 12 hours — supporting the morning-only dosing guideline.

Days to weeks (cumulative)

Some community users report cumulative neuroplasticity effects with repeated dosing — improved baseline mood, memory consolidation that persists between doses, reduced cognitive fatigue. Consistent with BDNF's known role in long-term synaptic plasticity. Not specific to Adamax.

Adamax's catecholaminergic mechanism (MC4R → dopamine/norepinephrine) makes behavioral and psychological effects relevant. Community reports:

• Motivational uplift: commonly reported, consistent with dopaminergic effects. This can be genuinely useful for productivity-focused users, or it can create a 'chasing the cognitive edge' pattern where users escalate dose seeking the initial clarity.
• Mood brightening: moderate, clean mood elevation described as different in character from antidepressant mood effects — situational and dose-related rather than baseline-shifting.
• Irritability at higher doses: the catecholamine modulation that produces focus can tip into irritability when the dose is too high or combined with significant caffeine. Particularly noted by some users at 800+ mcg.
• Psychological dependence risk: low based on community reports. The mechanism does not involve direct dopamine reward pathway activation in the way that stimulant drugs do. Some users report habitual use patterns, but escalating compulsive use is not a prominent community pattern for Semax-class compounds. Monitor for the impulse to use to 'feel normal' rather than to enhance — this pattern warrants a cycle break.

• Treating the '73% greater BDNF elevation' figure as published research: this claim circulates in community and commercial sources. The primary peer-reviewed study behind it cannot be independently verified. Treat it as an unverified commercial claim until a PubMed-indexed paper with this data can be identified.
• Not verifying which product 'Adamax' actually is: the naming confusion between N-Acetyl-Semax-Adamantane (the structural modification) and Semax+Selank blend products sold as 'Adamax' is the most important practical error in community use. You may be buying a different compound than you think.
• Assuming the adamantane group means indefinite stability: the adamantane protection extends half-life and reduces degradation compared to Semax, but Adamax is still a peptide that requires proper cold storage and timely use after reconstitution. Enhanced stability does not mean room-temperature storage is safe.
• Running Adamax simultaneously with Semax: redundant MC4R activation; adds stimulation burden without additional mechanism. Use one or the other.
• Expecting Adamax to be demonstrably better than N-Acetyl-Semax: the incremental improvement that Adamax's adamantane group provides over N-Acetyl-Semax (which already has improved stability and BBB penetration over standard Semax) may not be perceptible at community doses. Users who do not notice a clear difference from their N-Acetyl-Semax experience are not necessarily using a poor product — the pharmacological increment may be below the threshold of subjective detection.

Consistent with Semax cycling recommendations: 4-6 weeks on, 2-4 weeks off. The BDNF upregulation rationale: the brain may downregulate TrkB receptor density in response to sustained elevated BDNF signaling (consistent with other neurotrophin receptor regulation patterns). A break allows receptor density normalization before the next cycle. This is mechanistically inferred, not directly documented for Semax or Adamax. Community experience suggests consistent with this pattern — users who run Semax-class compounds continuously for months sometimes report diminishing returns, while those who cycle report maintained efficacy.

Adamax is a less common compound than Semax, Selank, or GHK-Cu in the research vendor market — fewer vendors carry it, batch quality is more variable, and the synthesis complexity (particularly the adamantyl conjugation step) creates more opportunities for substandard product. The primary sourcing concerns: (1) verification that the compound is the structural modification (N-Acetyl-Semax-Adamantane) and not a Semax/Selank blend sold under the same name — COA with mass spectrometry at ~1,200-1,300 Da is essential; (2) verification that the adamantyl group is correctly attached — HPLC purity alone does not confirm this; mass spec is required; (3) endotoxin testing below 0.1 EU/mg for injectable use. Pricing 2026: research vendor (full COA with mass spec), 10 mg Adamax: $60-120.

Adamax occupies the advanced nootropic peptide community niche — users who have typically already used Semax and N-Acetyl-Semax and are seeking a longer-duration, potentially more potent variant. The community is smaller than Semax's community and more technically engaged — partly because Adamax requires more due diligence to source correctly and partly because its pharmacology is more complex to understand without the Semax foundation. Community consensus on effects: qualitatively Semax-like (focus, clarity, BDNF-related mood and memory benefits) but with extended duration that allows once-daily morning dosing to cover the full cognitive workday. Community consensus on potency claims: divided — some users report clearly stronger effects than Semax at equivalent doses; others report similar effects. This division is consistent with either genuine inter-individual pharmacokinetic variation or expectation effects in a population that has specifically sought out a 'more potent' compound.

Dolotov OV, Karpenko EA, Inozemtseva LS, et al. (2006). Semax, an analog of ACTH(4-7) with cognitive effects, regulates BDNF and TrkB expression in the rat hippocampus. Journal of Neurochemistry. 100(2):470-479. PMID: 16996037. doi:10.1111/j.1471-4159.2006.04213.x. [THE independent Western replication — non-Russian, non-commercial; 1.4-fold BDNF protein, 1.6-fold TrkB phosphorylation, 3-fold BDNF mRNA; single dose 50 mcg/kg; improved conditioned avoidance; foundational paper for Semax's BDNF mechanism]

Stavchansky VV, Botsina AY, Salozhin SV, et al. (2024). Semax and its PGP fragment activate transcription of BDNF, NGF, TrkA, TrkB, and TrkC in ischemic rat cortex. Journal of Neurochemistry / PMC11498467. [2024 independent replication; both Semax and its PGP fragment activate BDNF/TrkB transcription in ischemia; BDNF and TrkC upregulated; confirms mechanism in disease model]

Vinogradova DV, et al. Studies on P21 peptide (CNTF-derived with adamantane modification) and CNS penetration. [P21 is the 4-amino acid peptide from which the adamantane C-terminal group concept is borrowed. P21 research demonstrated that the adamantyl group improves BBB penetration through lipophilicity enhancement — the key mechanistic basis for the adamantane modification in Adamax. Specific citations vary by source; search 'P21 peptide BDNF CNTF adamantane BBB penetration.']

General reference: Adamantane as a drug delivery scaffold — lipophilicity enhancement and CNS drug penetration literature. Key compounds for human exposure history: Amantadine (influenza/Parkinson's, FDA-approved 1966) and Memantine (Alzheimer's dementia, FDA-approved 2003) as established adamantane derivative pharmaceuticals with established human safety data.

Peptides Lab UK product page for Adamax (2025) [3]: 'Adamax as a standalone compound has no independent published studies indexed on PubMed as of 2025. It is a novel designer peptide and should be treated strictly as a research compound. The citations below relate to its constituent parent compounds — Semax and the P21 adamantane modification — which form the scientific basis for Adamax research.' [Vendor transparency disclosure; confirms Grade X status for Adamax-specific evidence]

Most appropriate for: advanced users who have already worked through Semax and N-Acetyl-Semax protocols, are familiar with the cognitive and neuroprotective effects of the ACTH analog class, and want to explore the next structural iteration with full awareness that they are operating on structural inference rather than compound-specific evidence. Users who understand that the 'potency upgrade' is claimed but not proven.

Not appropriate for: first-time nootropic users (start with Semax, which at least has a Russian clinical history); anyone who interprets vendor marketing claims as peer-reviewed evidence; anyone unwilling to conduct identity verification (mass spec COA) given the naming confusion in the market; anyone with psychiatric conditions that contraindicate catecholamine-modulating compounds.

Compound

Evidence Status

Duration

Primary Mechanism

Approved?

Semax

B — Dolotov 2006 independent replication

Short (4-6 hours)

MC4R, BDNF, TrkB

Russia (pharmaceutical)

N-Acetyl-Semax

C-D — structural inference + some study use

Moderate (6-8 hours)

Same + improved stability

Russia (variant form)

Adamax

X — no published study

Extended (8-10 hrs, claimed)

Same as Semax (inferred)

No

Selank

B — independent Dolotov replication; GABA

Short (4-6 hours)

GABA, enkephalin degradation inhibition

Russia (pharmaceutical)

Semax + Selank blend (also called 'Adamax' by some vendors)

B for components — no blend study

Mixed

Dual mechanism (BDNF + GABAergic)

No (blend not approved)

• 'Most potent Semax analog' = clinically proven superior to Semax: the potency claim is based on structural inference. No direct comparison between Adamax and Semax in any published study has confirmed greater potency by any objective measure.
• Vendor's 73% greater BDNF elevation figure = peer-reviewed evidence: this number circulates widely in community and commercial sources. It has not been located in a PubMed-indexed, peer-reviewed published study. It should be treated as an unverified commercial claim.
• Russian research tradition = Adamax has Russian research: Semax and Selank have Russian institutional research. Adamax is a novel designer compound that does not have an institutional research history in the same sense. The Russian framing is borrowed from the parent compound's lineage.
• Adamantane drug safety = Adamax safety: amantadine and memantine are safe, approved adamantane-derivative drugs. This does not directly establish the safety of the Adamax peptide-adamantane conjugate, whose metabolic behavior and breakdown products are uncharacterized.

— End of Adamax —

THE PEPTIDE BIBLE | Adamax (N-Acetyl-Semax Adamantylamine) | For Research & Educational Purposes Only